TGF‐β has been proposed as a potential therapeutic target in the treatment of COVID‐19 145 and previous studies suggest that epithelial TGF‐β1 acts as a principal trigger regulating lung injury and fibrosis.53 The gene discussed is TGFB1; the disease is COVID-19.